Hydralazine: Promising Epigenetic Treatment for Psoriasis?

In an astonishing development that piques the interest of medical researchers and dermatologists alike, a recent study published in the Journal of Translational Medicine has unveiled compelling evidence regarding the repurposing of hydralazine, a long-established antihypertensive medication, as a potential epigenetic modulator for treating psoriasis. This groundbreaking research, spearheaded by a team led by Dr. SE Wu, involves a meticulous retrospective analysis spanning 16 years of data from a nationwide cohort, revealing significant implications for psoriatic patients who have limited treatment options.

Psoriasis, a chronic autoimmune skin disorder, is characterized by the rapid proliferation of skin cells, leading to scaling and inflammation. Traditional therapies often focus on symptomatic relief but may come with undesirable side effects or variable efficacy among patients. This study presents an innovative approach by exploring the potential of hydralazine, traditionally used to treat high blood pressure, in addressing the root cause of psoriasis via epigenetic modulation.

The primary focus of this extensive study was to investigate the epigenetic mechanisms influenced by hydralazine, particularly its ability to modify gene expression without altering the underlying DNA sequence. By analyzing real-world patient data, the researchers sought to determine if those treated with hydralazine exhibited altered clinical outcomes for psoriasis compared to traditional treatments. This 16-year retrospective cohort study is among the first of its kind, adding significant weight to the argument for drug repurposing in dermatology.

One of the standout findings from this landmark study was the surprising normalization of cutaneous gene expression patterns in patients undergoing hydralazine treatment. By examining skin biopsies and clinical presentations, the researchers found that hydralazine could impact crucial pathways related to inflammation and hyperproliferation of keratinocytes, the primary cell type in the epidermis. This change at the molecular level has the potential to redefine the therapeutic landscape for psoriasis, which has long been characterized by a limited arsenal of effective treatment options.

The data showcased in Wu et al.’s study demonstrated that patients treated with hydralazine reported marked improvements in their psoriasis symptoms. This includes reduced plaque formation, decreased itching, and a lower incidence of psoriatic arthritis, a comorbid condition that complicates the lives of many psoriasis sufferers. Such results not only provide hope for patients seeking relief but also invite further investigation into the underside of hydralazine’s mode of action at an epigenetic level.

The implications of repurposing hydralazine extend beyond immediate clinical benefits. With increasing concerns regarding the safety profiles and accessibility of traditional systemic therapies, as well as the high costs associated with biologic treatments, this study holds the promise of both affordability and efficacy. For many patients, the idea of utilizing an existing medication with a well-documented safety history is immensely reassuring and potentially revolutionary.

Further, this research emphasizes the necessity for incorporating real-world evidence into clinical practice, shedding light on how everyday medications can be viewed through a new lens. By leveraging historical patient data, the researchers advocate for a more dynamic approach to treatment wherein existing drugs are reassessed and repurposed based on emerging insights into their pharmacodynamics and potential off-target effects.

Although the findings are promising, Wu and colleagues urge caution, highlighting the necessity for randomized controlled trials to validate the results of their retrospective analysis. Such studies would further elucidate the mechanisms through which hydralazine mediates its effects and establish robust clinical guidelines for its application in psoriasis treatment.

In addition to exploring hydralazine’s epigenetic properties, the researchers acknowledged potential molecular pathways, such as the modulation of histone acetylation and DNA methylation, that may play a crucial role in the development of psoriasis. Gaining a deeper understanding of these pathways could pave the way for more targeted epigenetic therapies in the future.

Moreover, the complex interplay between genetics, environment, and epigenetic factors in the development of psoriasis presents an intriguing avenue for future research. As the field continues to unravel the various layers of pathogenic mechanisms, drugs like hydralazine could find prominent positions in a multifaceted treatment strategy that addresses not only symptoms but also underlying causes.

The enthusiasm surrounding these findings was palpable among the medical community, particularly given the growing interest in repurposing existing medications for new therapeutic uses. The fundamental shift towards evidence-based practice, embracing data from various sources, signifies an evolution in the way researchers and practitioners view disease management. Reports such as this one could soon become catalysts for transformative change in dermatological care.

As we look ahead, the ongoing investigation into repurposing established medications such as hydralazine underscores a fundamental truth in medicine: existing therapies may serve uncharted paths that extend beyond their original indications. Thus, the exploration into hydralazine’s role as an epigenetic modulator could mark a significant leap forward in the quest for innovative solutions to chronic conditions like psoriasis.

In summary, Wu’s study sets an important precedent for the future of psychiatric disease management. By harnessing both the power of real-world evidence and the potential of drug repurposing, this research highlights not just a novel treatment avenue but an entirely new perspective on existing medications in the fight against stubborn ailments like psoriasis. With the healthcare landscape continuously evolving, the implications of this study may resonate far beyond the confines of dermatology, potentially reaching diverse areas that could benefit from a similar approach.

Wu, SE., Wang, W., Hung, CT. et al. Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study.
J Transl Med 23, 1296 (2025). https://doi.org/10.1186/s12967-025-07322-4